[Adjuvant tamoxifen in breast cancers with negative estrogen receptors. Complete review of the literature]

[Article in French]

Review

[Article in French]

M Namer et al. Bull Cancer. 1992.

. 1992;79(3):297-9.

No abstract available

Similar articles

Invasiveness gene signature predicts a favorable outcome also in estrogen receptor-positive primary breast cancers treated with adjuvant tamoxifen.
Coradini D, Gariboldi M, Fedeli M, Pierotti MA, Daidone MG. Coradini D, et al. Breast Cancer Res Treat. 2008 Sep;111(2):389-90. doi: 10.1007/s10549-007-9777-3. Epub 2007 Oct 4. Breast Cancer Res Treat. 2008. PMID: 17914668 No abstract available.
Tamoxifen for patients with estrogen receptor-negative breast cancer.
Swain SM. Swain SM. J Clin Oncol. 2001 Sep 15;19(18 Suppl):93S-97S. J Clin Oncol. 2001. PMID: 11560981 Review. No abstract available.
Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB, Feuer EJ, Harlan LC, Abrams J. Mariotto AB, et al. J Natl Cancer Inst Monogr. 2006;(36):7-15. doi: 10.1093/jncimonographs/lgj003. J Natl Cancer Inst Monogr. 2006. PMID: 17032888
Progesterone binding cyst protein in hormone receptor positive breast cancer; a predictive factor for effect of adjuvant tamoxifen treatment.
Søreide JA, Kolnes J, Skarstein A, Aas T, Kvinnsland S. Søreide JA, et al. Anticancer Res. 1994 Sep-Oct;14(5B):2105-8. Anticancer Res. 1994. PMID: 7840507 Clinical Trial.
[Tamoxifen: modern drug therapy of estrogen-dependent breast tumors].
Jovanović-Mićić D, Beleslin DB, Nikolić SS. Jovanović-Mićić D, et al. Med Pregl. 1996;49(7-8):287-90. Med Pregl. 1996. PMID: 8926945 Review. Croatian.